Cerus Corporation

Steritech, Inc.

Takeda Pharmaceutical Company Limited

The Dow Chemical Company

Sumitomo Pharma Switzerland Gmbh

Dowelanco

Myovant Sciences Gmbh

Susan Wollowitz

Henry Rapoport

Stephen T Isaacs

Hans Peter Spielmann

Aileen Nerio

David N Cook

Vijaykumar Reddy Rajasekhar

Brendan Mark Johnson

Paul N Mudd, Jr

Lynn Seely

Mark Hibberd

Masataka Tanimoto

Mayukh Vasant Sukhatme

Adonis Stassinopoulos

James E Dripps

Jan Matejovic

John E Merritt

William Alexander Denny

Sudarshan K Malhotra

Michael J Fazio

Richard A Wolf

John E Hearst

Edwin J Wilson

Ingrid L Knox

William Mariner Greenman

Michael R Dick

Ryan D Alfonso

Gregory A Bradfisch

Chi-Ping Chang

Jr Paul N Mudd

Methods for treating uterine fibroids, endometriosis, adenomyosis, or heavy menstrual bleeding in a subject, which include administering to the subject from 10 mg to 60 mg per day of N-(4-(1-(2,6-difluorobenzyl)-5-((dimethylamino)methyl)-3-(6-methoxy-3-pyridazinyl)-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidin-6-yl)phenyl)-N′-methoxyurea, and from 0.01 mg to 5 mg per day of a hormone replacement medicament. The present disclosure has methods for reducing menstrual bleeding in a subject, reducing bone mineral density loss in a subject caused by administering a GnRH antagonist to the subject, suppressing sex hormones in a subject, reducing vasomotor symptoms or hot flashes in a subject, and reducing symptoms of decreased libido in a subject having uterine fibroids, endometriosis, or adenomyosis. Further provided are methods of maintaining blood glucose profile, maintaining lipid profile, and/or maintaining bone mineral density in a pre-menopausal woman being treated for one or more conditions or symptoms of endometriosis, adenomyosis, uterine fibroids, or heavy menstrual bleeding; and methods of contraception and treating infertility.

Treatment of heavy menstrual bleeding associated with uterine fibroids

Methods for treating uterine fibroids, endometriosis, adenomyosis, or heavy menstrual bleeding in a subject, which include administering to the subject from 10 mg to 60 mg per day of N-(4-(1-(2,6-difluorobenzyl)-5-((dimethylamino)methyl)-3-(6-methoxy-3-pyridazinyl)-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidin-6-yl)phenyl)-N'-methoxyurea, and from 0.01 mg to 5 mg per day of a hormone replacement medicament. The present disclosure has methods for reducing menstrual bleeding in a subject, reducing bone mineral density loss in a subject caused by administering a GnRH antagonist to the subject, suppressing sex hormones in a subject, reducing vasomotor symptoms or hot flashes in a subject, and reducing symptoms of decreased libido in a subject having uterine fibroids, endometriosis, or adenomyosis. Further provided are methods of maintaining blood glucose profile, maintaining lipid profile, and/or maintaining bone mineral density in a pre-menopausal woman being treated for one or more conditions or symptoms of endometriosis, adenomyosis, uterine fibroids, or heavy menstrual bleeding; and methods of contraception and treating infertility.

Methods of treating endometriosis

Methods of treating uterine fibroids

Psoralen compound compositions are synthesized which have substitutions on the 4, 4&prime;, 5&prime;, and 8 positions of the psoralen, which yet permit their binding to nucleic acid of pathogens. Reaction conditions that photoactivate these bound psoralens result in covalent crosslinking to nucleic acid, thereby inactivating the pathogen. Higher psoralen binding levels and lower mutagenicity results in safer, more efficient, and reliable inactivation of pathogens. In addition to the psoralen compositions, the invention contemplates inactivating methods using the new psoralens.

Compounds for the photodecontamination of pathogens in blood

Compounds and methods for inactivating pathogens in materials are described, including compositions and methods for inactivating pathogens in biological materials such as red blood cell preparations and plasma. The compounds and methods may be used to treat materials intended for in vitro or in vivo use, such as clinical testing or transfusion. The compounds are designed to specifically bind to and react with nucleic acid, and then to degrade to form breakdown products. The degradation reaction is preferably slower than the reaction with nucleic acid.

Frangible compounds for pathogen inactivation

Method for photodecontamination of pathogens in blood using 5'-primary aminopsoralens

The present invention includes compositions comprising new psoralens with either a or primary amino substituent and a blood product that is suitable for in vivo use. The compositions are useful for the inactivation of pathogens in blood products such as platelets and plasma.

Psoralen compound compositions are synthesized which have primaryamino substitutions on the 3-, 4-, 5-, and 8-positions of the psoralen, which yet permit their binding to nucleic acid of pathogens. Reaction conditions that photoactivate these psoralens result in the inactivation of pathogens which contain nucleic acid. The compounds show similar activity in test systems to 4&prime; and 5&prime; derivatives of proralen useful for inactivation of pathogens in blood products. In addition to the psoralen compositions, the invention contemplates such inactivating methods using the new psoralens.

Psoralens for pathogen inactivation

Psoralen compounds

Methods and compositions for treating pathogens in material are described, including methods of decontaminating human fluids prior to processing in the clinical laboratory and methods for decontaminating blood products prior to in vivo use. The techniques handle large volumes of human serum without impairing the testing results. Novel compounds for photodecontaminating biological material are also contemplated which are compatible with clinical testing, in that they do not interfere with serum analytes.

Treating blood or blood products with compounds which have a mustard, azirdinium or aziridine group and a nucleic acid binding group

The present invention provides methods for inhibiting restenosis at a site of vascular recanalization. The methods include intravascular administration of a reactive acridine compound to the site of injury, without the requirement for activation or sustained release of the compound.

Inhibiting proliferation of arterial smooth muscle cells

Psoralen compounds are synthesized which have substitutions on the 4, 4&prime;, 5&prime;, and 8 positions of the psoralen, which permit enhanced binding to nucleic acid of pathogens. Higher psoralen binding levels and lower mutagenicity are described, resulting in safer, more efficient, and reliable inactivation of pathogens in blood products. The invention contemplates inactivation methods using the new psoralens which do not compromise the function of blood products for transfusion. In particular, use of 5&prime;-primary aminoalkyl psoralens to inactivate pathogens in platelets is disclosed.

5&prime;-primary aminoalkyl psoralen compositions with platelets

Psoralen compounds are synthesized which have substitutions on the 4, 4&prime;, 5&prime;, and 8 positions of the psoralen, which permit enhanced binding to nucleic acid of pathogens. Higher psoralen binding levels and lower mutagenicity are described, resulting in safer, more efficient, and reliable inactivation of pathogens in blood products. The invention contemplates inactivation methods using the new psoralens which do not compromise the function of blood products for transfusion.

Methods for photodecontamination of pathogens in blood

Methods and compositions for treating pathogens in material are described, including methods of decontaminating human fluids prior to processing in the clinical laboratory and methods for decontaminating blood products prior to in vivo use. The techniques handle large volumes of human serum without impairing the testing results.

Treating red blood cell solutions with anti-viral agents

Treating blood or blood product with a compound having a mustard and a nucleic acid binding moiety

Growing community of inventors

Walnut Creek, CA, United States of America

Susan Wollowitz